East Rutherford, NJ – Cambrex Corporation (NYSE: CBM, “Cambrex”) will be exhibiting its small molecule API products, services and technologies designed to accelerate the commercialization of finished drug products at InformexUSA 2012, February 15 -17 in New Orleans, LA. In addition, Cambrex personnel will be presenting at the Informex Exhibitor Showcase on February 14.
Cambrex will be showcasing its contract service capabilities ranging from development to finished dosage form manufacture with a portfolio of offerings that include controlled substances, high potency APIs, high energy chemistries, drug delivery and enzymatic biotransformation technologies. Cambrex manufactures over 120 generic and branded APIs, along with advanced pharmaceutical intermediates.
During the Informex Exhibitor Showcase, Dr. Kurt Kiewel, Director of Chemical Development at Cambrex Charles City, will present the latest developments in Cambrex’s high potency and controlled substance manufacturing capabilities. Dr. Kiewel supervises Cambrex Charles City’s High Potency Development Center, which provides containment and rigorous controls to reliably and safely develop and manufacture a wide range of high potency APIs and intermediates, including oncologics and controlled substances.
Cambrex is exhibiting at Booth 823 in the Morial Convention Center in New Orleans during InformexUSA.